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Background
Cdx4 is a homeobox gene essential for normal blood formation during embryonic development
in the zebrafish, through activation of posterior Hox genes. However, its role in adult mam-
malian hematopoiesis has not been extensively studied and its requirement in leukemia asso-
ciated with Hox gene expression alteration is unclear.
Design and Methods
We inactivated Cdx4 in mice through either a germline or conditional knockout approach and
analyzed requirement for Cdx4 in both normal adult hematopoiesis and leukemogenesis initi-
ated by the MLL-AF9 fusion oncogene. 
Results
Here,  we  report  that  loss  of  Cdx4 had  a  minimal  effect  on  adult  hematopoiesis.  Indeed,
although an increase in white blood cell counts was observed, no significant differences in the
distribution of mature blood cells, progenitors or stem cells were observed in Cdx4-deficient
animals. In addition, long-term repopulating activity in competitive transplantation assays was
not significantly altered. In vitro, B-cell progenitor clonogenic potential was reduced in Cdx4-
deficient animals but no significant alteration of mature B cells was detected in vivo. Finally,
induction of acute myeloid leukemia in mice by MLL-AF9 was significantly delayed in the
absence of Cdx4 in a retroviral transduction/bone marrow transplant model. 
Conclusions
These observations indicate that Cdx4 is dispensable for the establishment and maintenance of
normal hematopoiesis in adult mammals. These results, therefore, outline substantial differ-
ences in the Cdx-Hox axis between mammals and zebrafish and support the hypothesis that
Cdx factors are functionally redundant during mammalian hematopoietic development under
homeostatic conditions. In addition, our results suggest that Cdx4 participates in MLL-AF9-
mediated leukemogenesis supporting a role for Cdx factors in the pathogenesis of myeloid
leukemia. 
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ABSTRACT
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The  Cdx genes  are  the  mammalian  homolog  of  the
Drosophila caudal gene and encode homeobox transcrip-
tion factors that regulate axial elongation and anterior-pos-
terior patterning during embryogenesis through modula-
tion of Hox gene expression.
1-5 The Cdx gene family con-
sists of three members: Cdx1, Cdx2, and Cdx4.
6-8
Several studies have indicated a role for Cdx genes in
normal hematopoiesis during embryonic development. In
the  zebrafish  embryo,  cdx1 and  cdx4 are  important  for
blood  formation  through  activation  of  posterior  Hox
genes.
9,10 In addition, during in vitro hematopoietic differen-
tiation of murine embryonic stem cells (mESC), inactiva-
tion  of  Cdx4 results  in  reduced  hematopoietic  colony-
forming potential, which is almost completely abolished
upon  compound  Cdx1,  Cdx2,  and  Cdx4 inactivation.
6
Conversely, over-expression of Cdx1, Cdx2, or Cdx4 in
mESC was shown to facilitate early hematopoietic pro-
genitor  formation  through  up-regulation  of  Hox gene
expression.
6,7,9,11,12 Of  note,  Cdx4 over-expression  in  this
system  resulted  in  enhanced  formation  of  progenitors
with lymphoid repopulation capacity, suggesting a specif-
ic role for Cdx4 during lymphopoiesis.
11 Interestingly, sev-
eral studies have suggested a connection between Cdx4
and the mixed lineage leukemia gene, MLL, a master reg-
ulator of Hox gene expression
13-15 implicated in normal and
malignant hematopoiesis.
16 In support of this connection,
a similar pattern of Hox gene dysregulation is observed in
Mll
-/- and  Cdx4
-/- embryos.
13,14 In  addition,  in  vitro
hematopoietic differentiation of Mll
-/- mESC can be res-
cued by over-expression of Cdx4.
14 Finally, Cdx4 has been
found  to  interact  with  menin,  a  co-factor  of  MLL in
myeloid leukemogenesis
17,18 which participates in the con-
trol of Hox gene expression.
19 Taken together, these obser-
vations suggest that Cdx4 plays an important role in the
control  of  normal  embryonic  hematopoiesis,  likely
through a regulatory network involving Cdx4, Mll, and
Hox genes; however, they do not directly establish the
normal  function  of  Cdx4 in  adult  mammalian
hematopoiesis.
CDX genes  have  also  been  implicated  in  human
hematopoietic malignancies. CDX2 was found to be fused
to the ETV6 gene in the rare chromosomal translocation
t(12;13)(p13;q12) associated with acute myeloid leukemia
(AML),  resulting  in  its  deregulated  expression.
20
Subsequent studies identified aberrant CDX2 expression
in the majority of adult AML patients regardless of karyo  -
type.
21,22 In addition, CDX2 expression correlates with per-
sistence  of  minimal  residual  disease  and  has  been  pro-
posed  as  a  negative  prognostic  marker  in  acute  lym-
phoblastic  leukemia,
23,24 suggesting  that  CDX2 could  be
involved  in  both  myeloid  and  lymphoid  malignancies.
Similarly, aberrant expression of CDX4, located on chro-
mosome X, was also observed in patients with AML.
25
Consistent with a causal role in malignant transformation
of myeloid stem and progenitor cells, over-expression of
Cdx2 or Cdx4 in murine bone marrow transplant models
alters Hox gene expression and results in AML.
22,25,26
Despite their well-established role in leukemogenesis,
the physiological function of Cdx family members during
normal mammalian hematopoiesis remains incompletely
understood. We, therefore, assessed the consequences of
germline  and  conditional  Cdx4 deletion  in  mice.
Furthermore, we investigated the impact of Cdx4 loss on
the initiation and maintenance of AML induced by the
chimeric MLL-MLLT3 (also known and hereafter referred
to as MLL-AF9) fusion gene in a murine bone marrow
transplantation model.
Design and Methods
Generation of Cdx4 knockout mice
To create the conditional Cdx4 mouse strain, a targeting vector
containing loxP sites flanking the first exon, 5’ untranslated region
and the proximal promoter region of the Cdx4 gene was generated
(Figure  1B).  This  exon  encodes  the  majority  of  the  coding
sequence  of  CDX4 (165  out  of  282  amino  acids  including  the
homeodomain) and its excision would preclude expression of a
stable,  functional  protein.  This  construct  was  transfected  into
mESC,  and  ESC  clones  were  selected  with  hygromycin  and
screened by polymerase chain reaction (PCR) and Southern blot
analyses. Correctly targeted ESC (i.e. clone 9 shown in Figure 1)
were injected into Balb/C blastocysts to obtain chimeric animals
that were crossed with C57/B6 wild-type mice to obtain germline
transmission of the floxed Cdx4 allele (termed Cdx4
F). The Cdx4
F
allele was back-crossed for at least six generations with C57/B6
wild-type  animals  (Stock  #  000664,  The  Jackson  Laboratory).
Cdx4
F/WT were then bred with  Mx1-Cre transgenic animals and
interbred to obtain Cdx4
F/F Mx1-Cre (abbreviated Cdx4
F/F-Cre
+) ani-
mals and Cdx4
F/F control (abbreviated Cdx4
F/F-Cre
– or F/F-Cre
–) ani-
mals that were treated with polyinosinic-polycytidylic acid (pIpC;
Sigma, St. Louis, MO, USA; five intraperitoneal injections of 500
mg every other day). Excision efficiency was assessed by PCR with
the following primers: (i) Cdx4
-/- mice: WT-F: 5’-GCA CCT GCG
GTA TAA ATT CT-3’; WT-R: 5’-GCA ACT CAG AAC AGG TCC
TT-3’; GFP-F: 5’-TCA TCT GCA CCA CCG GCA A-3’; GFP-R: 5’-
GTT GTA GTT GTA CTC CAG CT-3’. Wild-type and mutant
alleles gave 200-bp and 300-bp PCR products, respectively; (ii)
Cdx4
F/F mice: WT-F5: 5’-CTT TAC GGA TGG TTG TGA GC-3’;
WT-R5: 5’-AGG ACA GGA ACT CAT GGA GTT T-3’; Exc-R1: 5’-
GGC CGC TCT AGA ACT AGT GGA-3’. Wild-type, floxed, and
excised alleles generated 200-bp, 250-bp, and 300-bp PCR prod-
ucts, respectively. Mice bearing a germline deletion of Cdx4 exon
1 (termed Cdx4
– allele) were described previously.
6 Approval for
the use of animals in this study was granted by the Children’s
Hospital Boston Animal Care and Use Committee.
Real-time quantitative reverse transcription 
polymerase chain reaction
Total RNA from sorted cells or hematopoietic tissues was isolat-
ed  using  the  Trizol  reagent  (Invitrogen).  RNA  samples  were
reverse-transcribed with the Superscript II kit (Invitrogen). Real-
time quantitative PCR assays for Cdx4 and β-actin (reference gene)
were obtained from Applied Biosystems (Mm00432451_m1 and
Mm01205647_g1, respectively). PCR were performed on an ABI-
7000 sequence detection system. The DDCt method was used to
calculate expression of Cdx4 relative to β-actin. Hox genes were
quantified as described previously.
25 All reactions were performed
on an ABI-7000 sequence detection system using SYBR Green
PCR Master Mix or Taqman Universal PCR Master Mix reagents
(Applied Biosystems).
Flow cytometry and cell sorting analyses 
Single-cell suspensions were prepared from bone marrow cells
after red blood cell lysis (Puregene). Cells were stained following
standard  procedures  using  antibodies  purchased  from  BD-
Pharmingen. Briefly, Lin
–Sca1
+cKit
+ (LSK) cells and myeloid pro-
genitors, including common myeloid progenitors (CMP), granulo-
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throcyte progenitors (MEP), were purified as follows. Total bone
marrow cells from 6- to 8-week old wild-type C57/Bl6 animals
were obtained after flushing the femora, tibiae and humeri and red
blood cells were lysed (Puregene RBC lysis buffer, Qiagen). Cells
were then stained with a cocktail of rat-anti-mouse antibodies
against  mature  cells  (lineage-positive  cells),  including  Ter119,
B220, CD3, CD4, CD8, IL7-R, CD19, and Gr1. After incubation
with sheep anti-rat antibody coated magnetic beads (Dynabeads
M-450, Dynal, Invitrogen), lineage-positive cells were physically
depleted using a magnet (Invitrogen). Cells were then incubated
with goat-anti rat PE-Cy5.5 conjugated antibody. After washing,
cells were blocked with rat IgG prior to incubation with anti-
CD34 FITC conjugated antibody, c-Kit APC conjugated antibody,
Sca-1  PE-Cy7  conjugated  antibody  (BD  Pharmingen)  and  Fcγ-
RII/III PE conjugated antibody (Abcam). Cells were flow sorted
using a double laser (488 nm/350 nm Enterprise II and 647nm
Pectrum)  FACS  (FACSAria,  BD  Biosciences).  For  T-cell  popula-
tions, thymocytes were obtained from 6- to 8-week old wild-type
C57/Bl6 animals. Cells were stained with anti-CD4, anti-CD8 and
anti-CD3 antibodies (BD Pharmingen) and populations were puri-
fied as indicated in Figure 1A. For B-cell populations, total bone
marrow cells from 6- to 8-week old wild-type C57/Bl6 animals
were stained with anti-B220, anti-CD19, anti-IgM and anti-CD43
and were purified using the gates exemplified in Figure 2B. Cells
were flow sorted using a double laser (488 nm/350 nm Enterprise
II  and  647nm  Pectrum)  FACS  (FACSAria,  BD  Biosciences)  and
analyses were carried out on a four-color FACSCalibur (Becton
Dickinson). Raw data were analyzed using FlowJo software.
Colony assays
Myeloid and pre-B colony-forming assays were performed by
plating 20,000 and 50,000 bone marrow cells per dish in duplicate
into  methylcellulose  medium  M3434  and  M3630  (Stem  Cell
Technologies,  Vancouver,  BC,  Canada),  respectively.  Colonies
were counted on day 7 and 10, respectively. Bone marrow cells
from  leukemic  mice  were  plated  in  methylcellulose  medium
M3434 at 10,000 cells per dish in duplicate. Colonies were count-
ed on day 7 and serially re-plated every 7 days at a density of
10,000 cells per dish.
Retroviral production, bone marrow transduction 
and transplantation assays
Retroviral supernatant production and bone marrow transplants
were performed as previously described
27 using MSCV-MLL-AF9-
GFP and MSCV-GFP. Briefly, 8-week old Cdx4
-/- or wild-type litter-
mate  donor  mice  were  injected  with  5-fluorouracil  (5-FU:  150
mg/kg) 5 days prior to bone marrow collection. On day 0, primary
bone marrow cells were obtained from femora and tibiae by flush-
ing with PBS 1x supplemented with 2% FBS; red blood cells were
lysed (Puregene, Qiagen) and cells were then cultured overnight in
RPMI 1640 supplemented with 10% FBS and IL3 (10 ng/mL), IL6
(20 ng/mL), SCF (10 ng/mL). Cells were mixed with similar titer
viral supernatants twice on day 1 and day 2, centrifuged for 90 min
at 2500 rpm and 33°C each time (spinfection) and returned to the
incubator for 2-3 hours. After the second spinfection, cells were
washed  and  re-suspended  in  Hank’s  balanced  salt  solution  1x
(HBSS 1x) and 1ﾥ10
6 cells were injected into the tail veins of each
lethally irradiated recipient. Animals were monitored daily for dis-
ease development and sacrificed according to institutional guide-
lines.
Non-competitive and competitive transplants were carried out
with two sets of donor mice in two independent experiments,
with five recipient mice per group in each experiment. CD45.2
+
bone  marrow  cells  from  Cdx4F/F
-Cre
+ and  control  donor  mice
were  injected  into  the  lateral  tail  veins  of  lethally  irradiated
CD45.1
+ C57/B6.SJL recipient mice, either alone for non-competi-
tive  transplants,  or  mixed  with  competitor  bone  marrow  cells
from wild-type F1 C57/B6 mice (CD45.1/2
+) for competitive trans-
plants (Figure 3c). Recipient mice were bled from the eyes every 4
weeks up to 16 weeks after transplantation for analysis of CD45
in the peripheral blood. Bone marrow cells were obtained from
recipient mice 16 weeks after transplantation for further analysis
of the CD45.2 donor contribution. 
Histopathology and microscopy
Peripheral blood was collected through non-lethal eye-bleeds
under anesthesia with isoflurane in accordance with institutional
guidelines.  Complete  blood  counts  were  determined  using  a
Hemavet 950 cell counter (Drew Scientific, Oxford, CT, USA).
Paraffin-embedded  tissue  sections  were  prepared  at  the  Dana
S. Koo et al.
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Figure 1. Cdx4 expression and conditional inactivation strategy. (A)
Quantitative real-time RT-PCR was used to measure Cdx4 mRNA
expression levels relative to β-actin in normal hematopoietic tissues
and flow sorted cells. BM: bone marrow; PB: peripheral blood; LSK,
enriched for hematopoietic stem cells; CMP common myeloid pro-
genitors; GMP, granulocyte-monocyte progenitors; MEP, megakary-
ocyte-erythroid progenitors. (B) Homologous recombination target-
ing strategy to obtain Cdx4
F/F mice. (C) Southern blot analysis using
the 3’ probe indicated in Panel B. WT: wild-type Cdx4 locus, Rec:
Cdx4 locus target by the conditional knock-out construct. Clone 9
showed homologous recombination and was used to generate the
conditional knock-out mouse line. Clone 8 was not correctly target-
ed, and demonstrates the germline configuration. (D) PCR to assess
Cdx4 excision 5 weeks after pIpC treatment was performed on DNA
from the indicated organs of Cdx4
F/F Mx1Cre
+ or Cdx4
F/F Mx1Cre
- ani-
mals using the three primers shown in Panel B (WT-F, WT-R, Exc-1R).
Flox: unexcised allele, Exc: Excised allele. (E) LSK cells and myeloid
progenitor  populations  from  Cdx4
F/F Mx1Cre
+ were  flow  sorted  6
weeks after pIpC treatment and DNA was extracted to assess exci-
sion  efficiency  as  described  in  (D).  DNA  from  untreated  Cdx4
F/F
Mx1Cre
+ total bone marrow cells was used as a control.  
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©Ferrata Storti FoundationFarber/Harvard  Cancer  Center  Specialized  Histopathology
Services Core and stained with hematoxylin and eosin. Images
were obtained using a Nikon Eclipse E400 microscope (Nikon,
Tokyo, Japan) and a SPOT RT color digital camera (Diagnostic
Instruments, Sterling Heights, MI, USA).
Statistical analysis
Statistical significance of differences between the results was
assessed by a two-tailed unpaired Student’s t-test using Prism soft-
ware.
Results
Cdx4 expression in normal murine hematopoeisis
We first determined the expression pattern of Cdx4 dur-
ing normal hematopoietic differentiation using quantita-
tive  reverse  transcription  PCR  on  RNA  from  wild-type
C57/B6  murine  hematopoietic  tissues  and  flow-sorted
progenitors. Cdx4 mRNA was preferentially expressed in
myeloid progenitor cells (Figure 1A) and during B-cell dif-
ferentiation.
Generation of conditional Cdx4 knockout mice
To establish the role of Cdx4 in normal hematopoiesis,
we engineered two mouse models of Cdx4 inactivation,
through either straight knockout
6 (named the Cdx4
– allele)
or conditional knockout (named the Cdx4
F allele) based
on inducible deletion of the entire exon 1 of the Cdx4
gene (Figure 1B). This was achieved through homologous
recombination in ESC; Southern blot analysis was per-
formed to select clones correctly targeted at the endoge-
nous Cdx4 locus on chromosome X (i.e. clone 9 but not
clone 8 in Figure 1C and Online Supplementary Figure S1).
After germline transmission of the Cdx4
– and Cdx4
F alle-
les, crosses were performed to obtain homozygous ani-
mals.  Both  Cdx4
-/- and  Cdx4
F/F knockout  animals  were
born at Mendelian ratios, appeared normal, had a weight
similar to their wild-type, age-matched littermates, and
were fertile. Cdx4
F/F mice were next crossed with Mx1-
Cre transgenic animals to allow for inducible Cre recom-
binase  expression.  Cdx4 excision  in  Cdx4
F/F-Mx1-Cre
(Cdx4
F/F-Cre
+ or F/F-Cre
+) mice was induced in 4- to 6-
week old animals by pIpC treatment. Subsequent analy-
ses  were  performed  4-6  weeks  after  pIpC  treatment
Cdx4 is dispensable for murine hematopoiesis
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Figure 2. Analysis of the hematopoietic compartment in Cdx4
F/F-Cre
+ mice. Flow cytometric analysis of the myeloid lineage (A) and B-cell lin-
eage (B) analyzed on bone marrow cells (n=4). Except where otherwise indicated, analyses were gated on total bone marrow cells. (C)
Histogram representation of results presented in Panel B (n=4). (D) Myeloid colony-forming potential of total bone marrow cells in SCF, IL3,
IL6 and EPO-supplemented methylcellulose cultures (M3434, StemCells). Colonies were scored 7 days after plating and the mean ± SD is
shown (n=4). GM, granulocyte macrophage; G/M, granulocyte or monocyte; GEMM, granulocyte erythroid macrophage megakaryocyte; BFU-
E, burst-forming unit-erythroid. (E) B-cell colony-forming potential of total bone marrow cells in IL7-supplemented methylcellulose cultures
(M3630, StemCells). Colonies were scored 10 days after plating and mean ± SD is shown (n=4). 
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©Ferrata Storti Foundationunless  otherwise  indicated.  Full  Cdx4 excision  was
observed in whole bone marrow (Figure 1D) as well as in
purified  hematopoietic  stem  and  progenitor-enriched
populations (Figure 1E). Full excision of Cdx4 in the bone
marrow was also demonstrated at 6 and 12 months (data
not shown), indicating that under homeostatic conditions,
there was no selective advantage for rare “escaper” cells in
which excision had not occurred.
Loss of Cdx4 results in minimal hematologic 
abnormalities
We then performed analyses of the peripheral blood and
hematopoietic organs. Both Cdx4
-/- and Cdx4
F/F-Cre
+ mice
showed a significant increase in the number of lympho-
cytes compared to their respective wild-type controls, as
assessed  by  an  automated  cell  counter  (Table  1,  Online
Supplementary Table S1). However, there was no consistent
difference  in  myeloid,  erythroid  and  platelets  counts,
absolute numbers and distribution of bone marrow cells
or spleen and liver weights between Cdx4 knockout mice
(Cdx4
-/- or Cdx4
F/F-Cre
+) and their respective littermate con-
trols  (Online  Supplementary  Table  S2).  Flow  cytometric
analyses of bone marrow cells from Cdx4 knockout mice
identified  no  significant  differences  in  the  major
hematopoietic  compartments  including  myeloid,  ery-
throid,  B-,  and  T-cell  lineages  (Figure  2A-C,  Online
Supplementary Figures S2A-C and S3). Similar results were
observed in a cohort of animals analyzed 8 and 12 months
after pIpC treatment (Online Supplementary Figure S4A,B
and data not shown).
To determine whether loss of Cdx4 affects the clono-
genic potential of hematopoietic progenitor populations,
we performed in vitro colony-forming unit (CFU) assays.
Compared to bone marrow from wild-type littermates,
Cdx4 knockout bone marrow produced similar total num-
bers of myeloid colonies, and no significant differences in
the distribution of colony types were observed (Figure 2D,
Online  Supplementary  Figure  S2D).  We  did,  however,
observe  a  significant  decrease  in  pre-B  colony-forming
activity in bone marrow cells from Cdx4 knockout mice
compared to bone marrow from their wild-type littermate
controls in both the conditional as well as the germline
knockout  model  (Figure  2E,  Online  Supplementary  Figure
S2E). Of note, we confirmed these observations in older
mice that were analyzed 8 and 12 months after pIpC treat-
ment.  (Online  Supplementary  Figure  S4C,D and  data  not
shown).
Loss of Cdx4 does not alter the number and repopulat-
ing activity of hematopoietic stem and progenitor cells
Since Cdx4 is expressed in the hematopoietic stem and
progenitor compartment, and was reported to be essential
for normal hematopoiesis in zebrafish,
9 we next assessed
the effect of loss of Cdx4 specifically on hematopoietic
stem  cell  function.  We  first  performed  multiparameter
flow cytometry analyses on the hematopoietic stem and
progenitor compartments. No significant differences in the
number  of  LSK,  CMP,  GMP,  or  MEP  were  observed
between  both  Cdx4 knockout  mouse  models  and  their
respective  wild-type  controls  (Figure  3A,B  and  data  not
shown). 
We then performed non-competitive and competitive
transplantation assays to assess the repopulating ability of
Cdx4-deficient  bone  marrow  cells.  CD45.1
–CD45.2
+
Cdx4
F/F-Cre
+ or  control  Cdx4
F/F-Cre
– bone  marrow  cells
were transplanted into lethally irradiated CD45.1
+CD45.2
–
B6/SJL  recipients  with  or  without  wild-type
CD45.1
+CD45.2
+ competitor  bone  marrow  cells  (Figure
3C). The contribution of the Cdx4-deficient and control
bone marrow cells to hematopoiesis in the recipients (per-
centage  of  CD45.1
-CD45.2
+ cells)  was  assessed  in  the
peripheral blood every 4 weeks over 16 weeks, and in the
bone marrow after 16 weeks. We observed a similar con-
tribution  of  donor-derived  CD45.1
-CD45.2
+ cells  from
Cdx4-deficient and littermate control mice in the peripher-
al blood (Figure 3D) and bone marrow of recipient mice
(data not shown). These results show that Cdx4-deficient
bone marrow cells are not significantly altered in their nor-
mal long-term repopulating ability, indicating that Cdx4 is
not  essential  for  hematopoietic  stem  cell  function  even
under the replicative stress associated with bone marrow
reconstitution.
Cdx4 shortens disease latency but is not essential for
MLL-AF9-induced leukemia in mice
Although  Cdx4 does  not  appear  to  be  essential  for
homeostatic  hematopoiesis,  it  was  previously  demon-
strated that in vitro differentiation of Mll
-/- ESC into blood
cells could be rescued by over-expressing Cdx4, suggesting
that Cdx4 might be epistatic to, or a critical downstream
effector of MLL.
14 Furthermore, oncogenic fusion proteins
involving  MLL  occur  frequently  in  patients  with  acute
myeloid or lymphoid leukemias. We, therefore, hypothe-
sized that Cdx4 might play a role in the context of MLL-
mediated  leukemogenesis.  To  test  this  idea,  we  used  a
murine model in which transplantation of bone marrow
cells  transduced  with  MLL-AF9 into  lethally  irradiated
recipients  induces  a  fully  penetrant  myeloid  leukemia
(Figure  4A).  Recipients  of  wild-type  bone  marrow  cells
transduced with MLL-AF9 developed acute leukemia with
a  median  latency  of  49  days.  In  contrast,  recipients  of
MLL-AF9-transduced Cdx4
-/- bone marrow cells developed
acute leukemia with a significantly longer latency of 63
days (P=0.0005) (Figure 4B). Histological analysis identi-
fied  no  morphological  differences  between  leukemias
derived  from  wild-type  and  Cdx4
-/- cells  (Online
Supplementary Figure S5). However, flow cytometric analy-
sis  revealed  that  while  leukemias  arising  in  both  back-
grounds showed a similar expansion of Mac1
+ cells in the
bone marrow (Figure 4C), leukemic cells generated on the
Cdx4
-/- background also displayed low levels of expression
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Table 1. Peripheral blood counts of Cdx4
F/F-Cre
+ and control animals. Blood
samples were taken 6-8 weeks after pIpC treatment from Cdx4
F/F-Cre
+ (n=10)
and Cdx4
F/F-Cre
+ (n=10) post-pIpC treatment and complete blood counts were
obtained with a Hemavet950 cell counter.
                                          Cdx4
F/F-Cre-               Cdx4
F/F-Cre+                t-test 
                                                (n=10)                        (n=10)                  (P value)
White blood cells (ﾥ10
9/L)   7.090±0.5695                   8.918±0.865                     0.0015
Lymphocytes (ﾥ10
9/L)           4.002±0.4485                   5.372±0.592                     0.0011
Granulocytes (ﾥ10
9/L)          1.635±0.2755                   1.835±0.283                     0.2431
Monocytes (ﾥ10
9/L)              0.3362±0.0572                 0.2962±0.042                    0.1974
Red blood cells (ﾥ10
12/L)     9.238±0.5336                  9.502±0.5608                    0.4230
Hematocrit (%)                       48.81±2.884                    52.02±2.722                     0.0755
Platelets (ﾥ10
9/L)                    443.4±47.69                    481.8±42.94                     0.1734
©Ferrata Storti Foundationof two lymphoid surface markers, CD3 and B220 (Figure
4D). Together, these studies suggest that Cdx4 is dispensa-
ble for leukemia induction by MLL-AF9, but its loss delays
disease onset and alters the leukemic phenotype in a bone
marrow transplantation model.
Loss of Cdx4 does not significantly affect Hox gene
expression
Cdx4 has been reported to regulate the expression of
Hox genes, including Hoxa9 and Hoxb4.
9,11,19 To determine
the effect of Cdx4 loss on Hox gene expression in murine
hematopoiesis, real-time quantitative RT-PCR was used to
measure the expression of several Hox genes in bone mar-
row cells from wild-type mice and Cdx4
-/- mice, as well as
in  leukemic  cells  generated  from  MLL-AF9-transduced
wild-type  and  Cdx4
-/- bone  marrow  cells.  This  analysis
showed that there were no significant differences in the
expression of individual Hox genes between Cdx4
-/- and
wild-type controls (Online Supplementary Figure S6).
Discussion
Here we report the first detailed analysis of the role of
a  caudal gene  in  adult  homeostatic  hematopoiesis  in
mammals  and  unexpectedly  demonstrate  that  Cdx4
knock-out  murine  models  do  not  present  major
hematopoietic defects. Indeed, in both germline and con-
ditional Cdx4 knockout models, hematopoietic stem and
progenitor cells as well as mature blood cells were not sig-
nificantly affected by Cdx4 loss of function. Of note, our
conditional Cdx4 knockout model bypasses any compen-
satory  mechanism  that  might  occur  during  embryonic
development  in  the  germline  Cdx4 knockout  model.
These results demonstrate that Cdx4 is not essential for
the  establishment  and  maintenance  of  normal  adult
hematopoietic stem cell functions in mice.
Although  these  results  contrast  with  the  severe
hematopoietic  defects  observed  in  cdx4 mutant
zebrafish,
9 it  is  important  to  note  that  mammals  have
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Figure 3. Analysis of the hematopoietic stem cell compartment in Cdx4
F/F-Cre
+ mice. (A) Flow cytometric analysis of the LSK (Lin
-c-Kit
+Sca1
+)
and myeloid progenitor compartments 4-6 weeks after pIpC treatment. Left panels show 10000 cells gated on viable Lin
- cells. Right panels
show 10000 cells gated on viable Lin
- c-Kit
+Sca1
- cells (B) Histogram representation of results presented in (A). Mean±SD are shown (n=4).
(C) Diagram showing non-competitive and competitive bone marrow repopulation assays. (D) Contribution of donor cells (CD45.2
+CD45.1
-)
to the hematopoiesis of lethally irradiated recipients in non-competitive and competitive transplants. The percentages of CD45.2
+ and
CD45.1
+ cells in the peripheral blood of recipient mice were measured by flow cytometric analysis at 4, 8, 12 and 16 weeks after transplan-
tations (n=5). Mean±SD of the percentage of CD45.2
+ cells are shown.  
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©Ferrata Storti Foundationthree Cdx genes (Cdx1, Cdx2, and Cdx4), whereas only
two  genes  have  been  assigned  to  the  Cdx family  in
zebrafish, cdx1 and cdx4. In addition, although zebrafish
cdx4 mutants have a severe hematopoietic defect,
9 knock-
down of cdx1 in a cdx4 mutant background results in a
complete failure to specify blood,
10 suggesting a minor
degree  of  redundancy  between  cdx1 and  cdx4 during
developmental hematopoiesis. It is likely that the critical
function  of  cdx genes  in  zebrafish  developmental
hematopoiesis can be extended to the functionally redun-
dant homolog Cdx2. In mammals, Cdx4 deficiency was
reported to cause a modest hematopoietic defect during in
vitro differentiation of mESC. In addition, although yolk
sac hematopoiesis was transiently altered before 9 days
post-conception,  no  significant  blood  alteration  was
observed in Cdx4 deficient embryos in the yolk sac 9 days
post-conception or in fetal liver. In contrast, Cdx2 defi-
ciency results in a more severe defect, and a combination
of  Cdx1,  Cdx2,  and  Cdx4 deficiency  almost  abolished
blood formation from mESC.
6 Furthermore, only Cdx2/4
compound  mutants,  but  not  Cdx4-deficient  or  Cdx1/4
double mutants, present axial elongation defects during
mouse development.
2 Together, these observations sug-
gest that Cdx4 may have a non-redundant role during
very early hematopoietic development but that its func-
tion in adult hematopoietic stem cells in vivo is compen-
sated  for  by  redundant  mechanisms.  This  difference
could be explained by a lower sensitivity to Cdx gene
dosage  in  definitive  compared  to  primitive
hematopoiesis.  An  alternative  possibility  is  that  Cdx
function is not essential for adult hematopoiesis. Indeed,
it was previously shown that other genes essential for
primitive hematopoiesis specification, such as SCL/Tal1,
do not play an essential role in definitive adult stem cell
function, supporting the existence of two distinct devel-
opmental  pathways  for  the  generation  of  embryonic
hematopoietic  stem  cells  and  maintenance  of  adult
hematopoietic stem cells. 
Although Cdx4 deficiency  was  not  associated  with  a
gross hematopoietic phenotype, our results do suggest a
previously unappreciated role for Cdx4 in lymphoid devel-
opment. Indeed, we show that Cdx4 expression is up-reg-
ulated in pre-B, pro-B, and B220
+ cells. We also observed a
reduced capacity of bone marrow cells from Cdx4-defi-
cient animals to form B-cell colonies in vitro. These obser-
vations are compatible with a positive role of Cdx4 in
lymphopoiesis that would result in a partial block of dif-
ferentiation during early B-cell development in Cdx4-defi-
S. Koo et al.
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Figure 4. Loss of Cdx4 delays MLL-AF9-induced leukemia. (A) Schematic of the retroviral transduction/bone marrow transplant protocol. (B)
Survival curves for cohorts of mice injected with wild-type (Cdx
+/+) or Cdx
-/- bone marrow cells transduced with MLL-AF9. Ten animals were
used in each group. (C) Flow cytometric analysis of bone marrow cells from recipient animals. Histograms on the right side represent
mean±SD of the percentage of the indicated population (n=3). (D) Flow cytometric analysis of expression of lymphoid markers on bone mar-
row cells from recipient animals.
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©Ferrata Storti Foundationcient animals. However, we also observed that lympho-
cyte blood counts were consistently higher in Cdx4-defi-
cient  animals  and  that  Cdx4-deficient  MLL-AF9-
transformed  blasts  aberrantly  express  some  lymphoid
markers, suggesting that Cdx4 deficiency accelerates and
promotes lymphoid differentiation. This latter hypothesis
suggests that Cdx4 restricts lymphoid identity. Although
these two hypotheses may not be mutually exclusive, fur-
ther studies are required to understand the precise role of
Cdx factors during lymphopoiesis. 
Aberrant  expression  of  CDX2 or  CDX4 genes  has
recently been implicated in the pathogenesis of human
AML, and it has been suggested that CDX proteins may,
at least in part, be responsible for the deregulated HOX
gene  expression  observed  in  the  majority  of  AML
cases.
8,22 In addition, Cdx4 can rescue the differentiation
of  Mll-deficient  ESC  in  vitro
14 and  has  been  shown  to
interact with menin in the up-regulation of Hoxa cluster
genes during Mll fusion-induced leukemogenesis,
19 sug-
gesting the possibility that oncogenic transformation by
MLL fusions  may  require  CDX4.  In  support  of  this
hypothesis,  we  found  that  although  Cdx4 is  not
absolutely required for leukemia induction by MLL-AF9,
its absence significantly prolonged the latency of disease
development. Moreover, the phenotype of the resultant
disease was altered with increased expression of B- and
T-lymphoid  markers  subsequent  to  Cdx4 loss.  Taken
together, this suggests a role for Cdx4 in MLL-induced
leukemogenesis. On the other hand, the subtlety of the
phenotype and the absence of a difference in Hox gene
expression between MLL-AF9-transduced wild-type and
Cdx4
-/- bone marrow cells, also point to a degree of func-
tional redundancy among Cdx factors in the context of
leukemogenesis. In addition, it is conceivable that there
are  context-specific  differences  in  the  requirement  for
Cdx4 during AML pathogenesis, depending on the under-
lying  mechanism  that  drives  the  leukemic  phenotype.
For example, mutant kinases, such as BCR-ABL1, which
do not have the potential for activating self-renewal pro-
grams  in  hematopoietic  cells,  may  be  more  reliant  on
Cdx4-controlled pathways than alleles such as the MLL
fusion genes that can confer self-renewal properties to
committed progenitors.
27-29
The minimal hematopoietic impairment upon loss of
Cdx4 along  with  its  aberrant  expression  in  acute
leukemias  make  CDX  proteins,  in  principle,  attractive
therapeutic targets. Indeed the therapeutic utility of target-
ing CDX2 was suggested by knockdown experiments in
AML cell lines.
22 Although targeting transcription factors is
very challenging and has not yet been clinically realized,
critical protein-protein interactions associated with tran-
scription factor function have recently been successfully
targeted with small molecule inhibitors making transcrip-
tion factors potentially “druggable” targets.
30 In this study,
we have shown that loss of Cdx4 significantly prolongs
the latency of disease onset in a mouse model of MLL-
AF9-induced AML. Although further studies will be neces-
sary to understand the full degree of redundancy between
Cdx genes in both normal and malignant hematopoiesis
and the precise role of these proteins in the context of
other MLL- or HOX-related leukemias, specific drug tar-
geting of CDX factors could be of value in AML.
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